"{\n \"business_address\": \"940 WINTER STREET, WALTHAM, MA 02451\", \n \"business_phone_no\": \"781 663 5776\", \n \"ceo\": \"Robert F. Friel\", \n \"cik\": \"0000031791\", \n \"company_url\": \"www.perkinelmer.com\", \n \"employees\": 8000, \n \"entity_legal_form\": \"CORPORATION\", \n \"entity_status\": \"ACTIVE\", \n \"hq_address1\": \"C/O C T Corporation System\", \n \"hq_address2\": \"155 Federal Street\", \n \"hq_address_city\": \"Boston\", \n \"hq_address_postal_code\": \"02110\", \n \"hq_country\": \"United States of America\", \n \"hq_state\": \"Massachusetts\", \n \"inc_country\": \"United States of America\", \n \"inc_state\": \"Massachusetts\", \n \"industry_category\": \"Health Services\", \n \"industry_group\": \"Medical Laboratories & Research\", \n \"latest_filing_date\": \"2017-08-08\", \n \"legal_name\": \"PERKINELMER INC\", \n \"lei\": \"549300IKL1SDPFI7N655\", \n \"long_description\": \"PerkinElmer, Inc. provides products, services, and solutions to the diagnostics, research, environmental, industrial, food, and laboratory services markets worldwide. The company operates through two segments, Discovery and Analytical Solutions and Diagnostics. The Discovery and Analytical Solutions segment develops and provides analytical technologies, solutions, and services that enable its customers to understand the characterization and health of various aspects, including air, water, and soil. It also provides solutions to farmers and food producers; an analytical instrumentation for the industrial market, which includes the chemical, electronics, energy, food, lubricant, petrochemical, and polymer industries; and laboratory services. This segment's offers a suite of solutions, including reagents, liquid handling systems, and detection and imaging technologies that enable scientists to enhance life sciences research and drug discovery processes. Its research portfolio includes a range of systems consisting of imaging, detection, and extraction instrumentation for use on in vitro, ex vivo, and in vivo models, analysis hardware, and software; and a range of consumable products, including drug discovery and research reagents. The Diagnostics segment provides early detection for genetic disorders from pregnancy to early childhood, as well as flat panel X-ray detectors and infectious disease testing for the diagnostics market. This segment also develops technologies that enable and support sample-to-sequencer workflow using next-generation DNA sequencing for applications in oncology, genetic testing, and drug discovery. The company serves pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies. PerkinElmer, Inc. was founded in 1931 and is headquartered in Waltham, Massachusetts.\", \n \"mailing_address\": \"940 WINTER STREET, WALTHAM, MA 02451\", \n \"name\": \"PerkinElmer Inc\", \n \"sector\": \"Healthcare\", \n \"securities\": [\n  {\n   \"composite_figi\": \"BBG000FXW512\", \n   \"composite_figi_ticker\": \"PKI:US\", \n   \"currency\": \"USD\", \n   \"delisted_security\": false, \n   \"etf\": false, \n   \"exch_symbol\": \"^XNYS\", \n   \"figi\": \"BBG000FXW512\", \n   \"figi_exch_cntry\": \"US\", \n   \"figi_ticker\": \"PKI:US\", \n   \"figi_uniqueid\": \"EQ0010050300001000\", \n   \"last_crsp_adj_date\": \"2017-10-19\", \n   \"market_sector\": \"Equity\", \n   \"mic\": \"XNYS\", \n   \"primary_listing\": true, \n   \"security_name\": \"PERKINELMER INC\", \n   \"security_type\": \"Common Stock\", \n   \"share_class_figi\": \"BBG001SBKS35\", \n   \"stock_exchange\": \"NYSE\", \n   \"ticker\": \"PKI\"\n  }, \n  {\n   \"composite_figi\": \"BBG000FP1JN9\", \n   \"composite_figi_ticker\": \"PKN:GR\", \n   \"currency\": \"EUR\", \n   \"delisted_security\": false, \n   \"etf\": false, \n   \"exch_symbol\": \"^XMUN\", \n   \"figi\": \"BBG000FP1MX1\", \n   \"figi_exch_cntry\": \"GM\", \n   \"figi_ticker\": \"PKN:GM\", \n   \"figi_uniqueid\": \"EQ0010050300001001\", \n   \"last_crsp_adj_date\": \"2017-10-19\", \n   \"market_sector\": \"Equity\", \n   \"mic\": \"XMUN\", \n   \"primary_listing\": false, \n   \"security_name\": \"PERKINELMER, INC.\", \n   \"security_type\": \"Common Stock\", \n   \"share_class_figi\": \"BBG001SBKS35\", \n   \"stock_exchange\": \"MUN\", \n   \"ticker\": \"PKN\"\n  }, \n  {\n   \"composite_figi\": \"BBG000FP1JN9\", \n   \"composite_figi_ticker\": \"PKN:GR\", \n   \"currency\": \"EUR\", \n   \"delisted_security\": false, \n   \"etf\": false, \n   \"exch_symbol\": \"^XDUS\", \n   \"figi\": \"BBG000FP1KN6\", \n   \"figi_exch_cntry\": \"GD\", \n   \"figi_ticker\": \"PKN:GD\", \n   \"figi_uniqueid\": \"EQ0010050300001001\", \n   \"last_crsp_adj_date\": \"2017-10-19\", \n   \"market_sector\": \"Equity\", \n   \"mic\": \"XDUS\", \n   \"primary_listing\": false, \n   \"security_name\": \"PERKINELMER, INC.\", \n   \"security_type\": \"Common Stock\", \n   \"share_class_figi\": \"BBG001SBKS35\", \n   \"stock_exchange\": \"DUS\", \n   \"ticker\": \"PKN\"\n  }, \n  {\n   \"composite_figi\": \"BBG000FP1JN9\", \n   \"composite_figi_ticker\": \"PKN:GR\", \n   \"currency\": \"EUR\", \n   \"delisted_security\": true, \n   \"etf\": false, \n   \"exch_symbol\": \"^XETR\", \n   \"figi\": \"BBG000FP1JN9\", \n   \"figi_exch_cntry\": \"GR\", \n   \"figi_ticker\": \"PKN:GR\", \n   \"figi_uniqueid\": \"EQ0010050300001001\", \n   \"last_crsp_adj_date\": null, \n   \"market_sector\": \"Equity\", \n   \"mic\": \"XETR\", \n   \"primary_listing\": false, \n   \"security_name\": \"PERKINELMER, INC.\", \n   \"security_type\": \"Common Stock\", \n   \"share_class_figi\": \"BBG001SBKS35\", \n   \"stock_exchange\": \"XETRA\", \n   \"ticker\": \"PKN\"\n  }, \n  {\n   \"composite_figi\": \"BBG000FP1JN9\", \n   \"composite_figi_ticker\": \"PKN:GR\", \n   \"currency\": \"EUR\", \n   \"delisted_security\": false, \n   \"etf\": false, \n   \"exch_symbol\": \"^XFRA\", \n   \"figi\": \"BBG000FP1K92\", \n   \"figi_exch_cntry\": \"GF\", \n   \"figi_ticker\": \"PKN:GF\", \n   \"figi_uniqueid\": \"EQ0010050300001001\", \n   \"last_crsp_adj_date\": \"2017-10-19\", \n   \"market_sector\": \"Equity\", \n   \"mic\": \"XFRA\", \n   \"primary_listing\": false, \n   \"security_name\": \"PERKINELMER INC\", \n   \"security_type\": \"Common Stock\", \n   \"share_class_figi\": \"BBG001SBKS35\", \n   \"stock_exchange\": \"FRA\", \n   \"ticker\": \"PKN\"\n  }, \n  {\n   \"composite_figi\": \"BBG000FP1JN9\", \n   \"composite_figi_ticker\": \"PKN:GR\", \n   \"currency\": \"EUR\", \n   \"delisted_security\": false, \n   \"etf\": false, \n   \"exch_symbol\": \"^XSTU\", \n   \"figi\": \"BBG000FP1M16\", \n   \"figi_exch_cntry\": \"GS\", \n   \"figi_ticker\": \"PKN:GS\", \n   \"figi_uniqueid\": \"EQ0010050300001001\", \n   \"last_crsp_adj_date\": \"2017-10-19\", \n   \"market_sector\": \"Equity\", \n   \"mic\": \"XSTU\", \n   \"primary_listing\": false, \n   \"security_name\": \"PERKINELMER, INC.\", \n   \"security_type\": \"Common Stock\", \n   \"share_class_figi\": \"BBG001SBKS35\", \n   \"stock_exchange\": \"STU\", \n   \"ticker\": \"PKN\"\n  }, \n  {\n   \"composite_figi\": \"BBG000FP1JN9\", \n   \"composite_figi_ticker\": \"PKN:GR\", \n   \"currency\": \"EUR\", \n   \"delisted_security\": false, \n   \"etf\": false, \n   \"exch_symbol\": \"^XBER\", \n   \"figi\": \"BBG000FP1P91\", \n   \"figi_exch_cntry\": \"GB\", \n   \"figi_ticker\": \"PKN:GB\", \n   \"figi_uniqueid\": \"EQ0010050300001001\", \n   \"last_crsp_adj_date\": \"2017-10-19\", \n   \"market_sector\": \"Equity\", \n   \"mic\": \"XBER\", \n   \"primary_listing\": false, \n   \"security_name\": \"PERKINELMER, INC.\", \n   \"security_type\": \"Common Stock\", \n   \"share_class_figi\": \"BBG001SBKS35\", \n   \"stock_exchange\": \"BER\", \n   \"ticker\": \"PKN\"\n  }\n ], \n \"short_description\": \"PerkinElmer, Inc. (United States) engages in the provision of products and solutions to diagnostics, research, and laboratory services. it operates through the Human Health and Environmental Health segments. The Human Health segment researches and develops therapies such as genetic disorder detections, screening products, infectious disease testing, drug discoveries. The Environmental Health segment produces and sells products and solutions which include harmful substances detection in food, water, and surroundings. The company was founded by Richard Scott Perkin and Charles W. Elmer on April 19, 1937 and is headquartered in Waltham, MA.\", \n \"sic\": 3826, \n \"standardized_active\": true, \n \"stock_exchange\": \"NYSE\", \n \"template\": \"industrial\", \n \"ticker\": \"PKI\"\n}"